Women bothered by hot flashes or other effects of menopause have a number of treatment options -- hormonal or not, according to updated guidelines from the American College of Obstetricians and Gynecologists. It's estimated that anywhere ...
Tags: hot flashes, menopause, women health
The European Medicines Agency (EMA) has accepted Shionogi's marketing authorisation application (MAA) for ospemifene. Ospemifene is developed as as vulvar and vaginal atrophy (VVA) therapy in post-menopausal women. Shionogi CEO Takashi ...
Tags: EMA, Medicines, ospemifene
Food and Drug Administration (FDA) has approved US-based pharmaceutical company Shionogi's Osphena (ospemifene) tablets for the treatment of moderate to severe dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy ...
Tags: FDA, Dyspareunia, Medicine